LoQus23 Therapeutics Advances First-in-Class Huntington’s Disease Candidate LQT-23 Into Preclinical Development

LoQus23 Therapeutics Ltd has shared an update.

The company announced the nomination and progression of LQT-23, described as a potent, first-in-class small molecule allosteric inhibitor of MSH3/MutSβ, as its lead drug candidate for Huntington’s disease (HD). LQT-23 is positioned as the most advanced small molecule inhibitor of MutSβ to date, targeting DNA mismatch repair pathways that have been implicated as key drivers of HD and other triplet repeat disorders. LoQus23 plans to continue preclinical development of LQT-23 through the current year.

For investors, this development marks a significant pipeline milestone that could enhance the company’s long-term value proposition if preclinical and subsequent clinical data validate the therapeutic potential and safety of LQT-23. Targeting MSH3/MutSβ, a challenging but promising mechanism, may provide LoQus23 with meaningful differentiation in the HD drug development landscape, where there are currently no approved disease-modifying treatments. Successful advancement toward clinical trials could improve the company’s prospects for future partnering, non-dilutive funding, or eventual exit opportunities. However, the program remains at a preclinical stage, and associated scientific, regulatory, and execution risks remain high, with timelines to potential revenue likely to be long and dependent on future trial outcomes and financing capacity within a competitive neurodegenerative disease pipeline environment.